Articles by Karen Carey

GlycoGenesys To Advance GCS-100 With $20M Funding

Oct. 25, 2005

Syntonix, Boehringer Enter $63M Inhaled Peptide Deal

Oct. 24, 2005

For the second time this year, an international drug company is showing a strong interest in Syntonix Pharmaceuticals Inc.'s Synfusion and Transceptor technologies - this time to the tune of up to $63 million. (BioWorld Today)

Alinea Brings In $45M For Diabetes, Metabolic Programs

Oct. 21, 2005

By Karen Carey

Cardium Acquires Portfolio From Schering, Raises $28.5M

Oct. 21, 2005

By Karen Carey

With Neurodex Filed With FDA, Avanir Raises $16M

Oct. 20, 2005

By Karen Carey

Sonus, Schering In Tocosol Paclitaxel Deal Worth $168M

Oct. 19, 2005

By Karen Carey

After starting a pivotal trial last month, Sonus Pharmaceuticals Inc. now has secured a sweet deal for its cancer product Tocosol Paclitaxel, giving exclusive worldwide rights to Schering AG. (BioWorld Today)

Memory Partners With Amgen Over PDE10 Inhibitor Program

Oct. 18, 2005

By Karen Carey

Voyager Sets IPO Range, Starts Memryte Phase III

Oct. 17, 2005

By Karen Carey

Array Gains $50M More Through Extended Oncology Agreement

Oct. 14, 2005

By Karen Carey

Array BioPharma Inc. expanded its oncology collaboration with Genentech Inc. for the second time, securing a potential $50 million in additional research funding over the next three years. (BioWorld Today)

Positive Tadalafil Data In BPH Starts Phase III Plans For ICOS

Oct. 13, 2005

By Karen Carey

Lilly ICOS LLC plans to move tadalafil into a Phase III program for benign prostatic hyperplasia after it reached statistical significance in a Phase II proof-of-concept study. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...